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The Role of Hydrogen Sulfide in
Renal System
Xu Cao and Jin-Song Bian*
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Hydrogen sulfide has gained recognition as the third gaseous signaling molecule after
nitric oxide and carbon monoxide. This review surveys the emerging role of H2S in
mammalian renal system, with emphasis on both renal physiology and diseases. H2S
is produced redundantly by four pathways in kidney, indicating the abundance of
this gaseous molecule in the organ. In physiological conditions, H2S was found to
regulate the excretory function of the kidney possibly by the inhibitory effect on sodium
transporters on renal tubular cells. Likewise, it also influences the release of renin from
juxtaglomerular cells and thereby modulates blood pressure. A possible role of H2S
as an oxygen sensor has also been discussed, especially at renal medulla. Alternation
of H2S level has been implicated in various pathological conditions such as renal
ischemia/reperfusion, obstructive nephropathy, diabetic nephropathy, and hypertensive
nephropathy. Moreover, H2S donors exhibit broad beneficial effects in renal diseases
although a few conflicts need to be resolved. Further research reveals that multiple
mechanisms are underlying the protective effects of H2S, including anti-inflammation,
anti-oxidation, and anti-apoptosis. In the review, several research directions are also
proposed including the role of mitochondrial H2S in renal diseases, H2S delivery
to kidney by targeting D-amino acid oxidase/3-mercaptopyruvate sulfurtransferase
(DAO/3-MST) pathway, effect of drug-like H2S donors in kidney diseases and
understanding the molecular mechanism of H2S. The completion of the studies in these
directions will not only improves our understanding of renal H2S functions but may also
be critical to translate H2S to be a new therapy for renal diseases.
Keywords: hydrogen sulfide, H2S, renal physiology, acute kidney injury, chronic kidney disease, diabetic
nephropathy
INTRODUCTION
Hydrogen sulfide has been regarded as a toxic gas for 100s of years (Smith and Gosselin, 1979).
It can directly inhibit the activity of several essential enzymes in human namely cytochrome c
oxidase (Reiffenstein et al., 1992), carbonic anhydrase (Nicholson et al., 1998), monoamine oxidase
(Warenycia et al., 1989), and Na+/K+ ATPase (Reiffenstein et al., 1992), thereby causing toxicity.
Abbreviations: AC, adenylate cyclase; AMPK, 5′ AMP-activated protein kinase; AOAA, aminooxyacetic acid; CaMTg,
pancreatic β-cell specific calmodulin-overexpressing transgenic; CAT, cysteine aminotransferase; CBS, cystathionine
β-synthase; CKD, chronic kidney disease; CO, carbon monoxide; CSE, cystathionine γ-lyase; DAO, D-amino acid oxidase;
DN, diabetic nephropathy; EDHF, endothelium-derived hyperpolarizing factor; EDRF, endothelium-derived relaxing factor;
GFR, glomerular filtration rate; H2S, hydrogen sulfide; IRI, ischemia/reperfusion injury; JG, juxtaglomerular; MAPK,
mitogen-activated protein kinase; MMP-9, matrix metalloproteinase-9; NF-κB, nuclear factor-κB; NKA, Na+/K+ ATPase;
NKCC, Na+/K+/2Cl− cotransporter; NO, nitric oxide; PAG, DL-propargylglycine; RAS, renin–angiotensin system; ROS,
reactive oxygen species; STZ, streptozotocin; Uk·V, urinary potassium; UNa·V, urinary sodium; VEGF, vascular endothelial
growth factor; 3-MP, 3-mercaptopyruvate; 3-MST, 3-mercaptopyruvate sulfurtransferase.
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However, the image of H2S has been largely expanded since
the revelation of H2S as an endogenous neuronal modulator
by Kimura’s group in Abe and Kimura (1996). Thereafter, the
physiological significance of H2S has been extensively studied
especially in central nervous system (Zhang and Bian, 2014) and
cardiovascular system (Liu et al., 2012). Emerging evidence has
suggested that H2S also actively regulates renal function and is
implicated in numerous kidney diseases in recent years. Here in
this review, recent studies regarded the role of H2S in both kidney
physiology and diseases will be discussed.
PHYSICAL AND CHEMICAL
PROPERTIES OF H2S
Hydrogen sulfide exists as a colorless gas with a strong rotten egg
smell at room temperature and ambient pressure. The human
nose can detect a concentration of 400-fold lower than its toxic
level (Wang, 2002), whereas, long term exposure can cause
desensitization of olfactory nerves to H2S (Li et al., 2009). Distinct
from the other gaseous transmitters like NO and CO, H2S is a
weak acid and hence able to readily dissolve in water. Based on
its PKa, it is estimated that there will be 14% H2S gas, 86% HS−
and a trace of S2− in physiological condition (pH 7.4, 37◦C; Li
et al., 2009). Moreover, H2S gas is highly lipophilic which allows it
freely to penetrate into the cell membrane of all types and become
biologically active (Mathai et al., 2009).
H2S GENERATION IN THE KIDNEY
Three traditional H2S synthesizing pathways have been identified
in mammalians including CSE (EC 4.4.1.1), CBS (EC 4.2.1.22),
and 3-MST (EC 2.8.1.2) coupled with CAT (EC 2.6.1.3) pathways.
The mechanisms underlying these traditional pathways can be
found in our previous review in detail (Liu et al., 2012). In
short, CSE firstly dimerizes two L-cysteine to L-cystine followed
by transforming it into pyruvate, NH3 and thiocysteine. The
resulted thiocystein is then used as a substrate by CSE to react
with other thiols to generate H2S (Stipanuk and King, 1982). CBS
catalyzes the reaction between L-cysteine and homocystenin into
cystathinine and H2S (Szabo, 2007). However, 3-MST is unable
to directly use L-cysteine as a substrate as its counterpart does.
L-cysteine has to be transformed into 3-MP by CAT which is
then catalyzed by 3-MST into pyruvate and H2S (Shibuya et al.,
2009). It is worth mentioning that both CSE and CBS require
pyridoxal 5′-phosphate as a cofactor to synthesize H2S, while
3-MST is dependent on zinc (Li et al., 2009). In addition, CSE
and CBS mainly locate in cytosol yet they can translocate into
mitochondria in some oxidative conditions (Fu et al., 2012),
whereas 3-MST resides and generates H2S in mitochondria
(Kimura, 2011).
A fourth H2S generation pathway namely DAO/3-MST
pathway was discovered recently by Kimura’s group (Shibuya
et al., 2013). In the study, they showed that kidney lysate can
produce 60 times more H2S when using D-cysteine as substrate
comparing with L-cysteine. Further, the underlying mechanism
was studied. Specifically, D-cysteine is transformed into 3-MP
by peroxisome located DAO. Due to metabolite exchanges
between peroxisome and mitochondria, 3-MP is imported into
mitochondria and catalyzed into H2S by 3-MST. Since DAO is
only located in brain and kidney, this H2S generating pathway is
believed to exclusively exist in brain and kidney.
Hydrogen sulfide generation is abundant in kidney given the
presence of all the above mentioned pathways in this organ
(Figure 1). Currently, it is believed that CSE and CBS are the
dominated enzymes for H2S generation in kidney. The presence
of these two enzymes was firstly demonstrated in 1980s by using
their inhibitors (Stipanuk and Beck, 1982). Later on, House et al.
(1997) suggested that both enzymes were mainly located on
renal proximal tubules within the renal cortex by comparison
with marker enzymes of known location. This finding was
supported by several other studies using different methods (Ishii
et al., 2004; Li et al., 2006; Tripatara et al., 2009). However,
inconsistent results have been reported regarding the existence
of these two enzymes in glomerulus which needs to be resolved
(Aminzadeh and Vaziri, 2012; Bos et al., 2013; Yamamoto
et al., 2013). In addition, definitive evidence has suggested the
presence of 3-MST in kidney (Aminzadeh and Vaziri, 2012;
Shibuya et al., 2013; Kimura, 2014; Pan et al., 2015), however,
the significance of 3-MST mediated H2S generating pathway
has not been well-acknowledged in both kidney physiology and
diseases due to limited reports. Nevertheless, the revelation of
the unique DAO/3-MST pathway in kidney and brain may imply
a significant role of 3-MST mediated H2S generation in these
organs. This will be an interesting area open to explore in the next
years.
EFFECT OF H2S ON RENAL
PHYSIOLOGY
H2S Effect on Renal Excretory Function
The necessity of H2S producing enzymes have long been
recognized in the kidney due to their critical effect on
homocysteine metabolism (Stipanuk, 2004), however, the effect
of H2S itself on renal function was not studied until recently.
Intra-renal infusion of H2S donor NaHS is able to increase GFR,
UNa·V and potassium (Uk·V) excretion (Xia et al., 2009; Ge
et al., 2014). Moreover, the effect is closely mimicked by the
infusion of L-cysteine, an H2S generating substrate (Xia et al.,
2009). In addition, inhibition of endogenous H2S production
by AOAA (CBS inhibitor) plus PAG (CSE inhibitor) leads to
the decrease of GFR, UNa·V and Uk·V, suggesting that H2S
regulates renal function in physiological conditions. However,
either AOAA or PAG alone fails to produce any effect on renal
function implicating a compensatory effect between CBS and CSE
on renal regulation which has been confirmed by another study
(Roy et al., 2012). Hypothesis concerning the effects of H2S on
sodium transporters was formed and tested thereafter. The results
showed that H2S significantly inhibited the activity of NKCC
and NKA which may account for its effect on renal function
(Figure 2A). Recently, the mechanism of the inhibitory effect of
H2S on NKA was studied by Zhu’s group (Ge et al., 2014). In
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FIGURE 1 | Endogenous synthesis of H2S by four pathways in renal system. (1) CBS mediated H2S synthesis by using L-cysteine as the substrate in cytosol;
(2) CSE mediated H2S synthesis with L-cysteine as the substrate in cytosol; (3) CAT transforms L-cysteine into 3MP which is further catalyzed by 3-MST into H2S in
mitochondria; (4) Peroxisome resident DAO catalyzes D-cysteine into 3MP which is then exchanged into mitochondria and utilized by 3-MST for the production of
H2S in mitochondria. CBS, cystathionine β-synthase; CSE, cystathionine γ-lyase; 3-MST, 3-mercaptopyruvate sulfurtransferase; CAT, cysteine aminotransferase;
DAO, D-amino acid oxidase; 3MP, 3-mercaptopyruvate.
their study, they showed that NaHS promoted NKA endocytosis
by directly activating epidermal growth factor receptor (EGFR)
in renal tubular epithelia cells. Moreover, EGFR cys797 mutation
fully abolished the effect of H2S suggesting a direct interaction
between H2S and this cysteine residue. Taken together, both
endogenous and exogenous H2S are able to increase GFR, UNa·V,
and Uk·V excretion probably through the inhibitory effect on
sodium transporters like NKCC and NKA.
Hydrogen sulfide increases Cl−/HCO3− exchanger activity
in various tissues like aortic tissues (Liu and Bian, 2010) and
vascular smooth muscle cells (Lee et al., 2007). However, the effect
of H2S on the exchanger in kidney is still unknown. It is likely
that H2S can also enhance the activity of Cl−/HCO3− exchanger
in renal system. Considering the critical role of Cl−/HCO3−
exchanger in regulating the excretion of ions and homeostatic
maintenance of physiological pH, it will be of great value to
reveal the effect of H2S on Cl−/HCO3− exchanger activity and
the subsequent consequence in kidney.
H2S Effect on Renin Release
The RAS is a renovascular hormone system involved in the
regulation of plasma sodium concentration and blood pressure
(BP). Renin release from JG cells determines RAS activity and
the process is known to be regulated by intracellular cAMP
(Peters et al., 1993; Gambaryan et al., 1998; Schweda et al.,
2007). Moreover, H2S was reported to downregulate cAMP
level in several cell types (Lim et al., 2008; Yong et al.,
2008), implying that H2S may modulate renin release. This
was demonstrated by our group in Lu et al. (2010). It was
found that NaHS inhibited the upregulation of renin mRNA
and protein level in a model of renovascular hypertension
accompanying with a reduction of intracellular cAMP level.
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FIGURE 2 | Effects of H2S on renal regulation. (A) H2S inhibits the activity of tubular NKCC and NKA, thereby enhancing renal excretory function such as GFR,
UNa.V and Uk.V. (B) H2S suppresses renin release by inhibition of AC activity and ROS production in GC cells. (C) H2S as an O2 sensor in the kidney. In normoxic
condition, H2S is metabolized into sulfates in the presence of O2; in hypoxic condition, the shortage of O2 leads to the accumulation of H2S which helps to restore
O2 level by enhancing blood flow and suppressing tubular transport activity in kidney. NKCC, Na+/K+/2Cl− cotransporter; NKA, Na+/K+ ATPase; GFR, glomerular
filtration rate; UNa·V, urinary sodium; Uk·V, urinary potassium; β1, β1-adrenoceptor; ROS, reactive oxygen species; ATP, adenosine triphosphate; cAMP, cyclic
adenosine monophosphate; JG cell, juxtaglomerular cell.
This is supported by another study (Lu et al., 2012) showing
that H2S regulates renin degranulation in As4.1 and rat renin-
rich kidney cells stimulated by isoproterenol, forskolin or 3-
isobutyl-1-methylxanthine. Further study demonstrated that H2S
significantly suppressed the stimulated AC activity in these cells.
Overexpression of CSE also attenuates isoproterenol-induced
renin release suggesting that endogenous H2S may also involve in
the process. However, the mechanism underlying the inhibitory
effect of H2S on AC remains to be determined, such as the
identification of AC isoform(s) accounting for H2S effect and
the molecular interaction between H2S and the AC isoform(s).
Besides AC, ROS was recently reported to be a target of H2S
for its effect on renin reduction in DN suggesting participation
of multiple mechanisms in the process (Xue et al., 2013).
The effect of H2S on renin activity in normal rats has also
been investigated (Lu et al., 2010). The results showed that
neither NaHS administration nor inhibition of endogenous H2S
influenced renin activity implying that H2S may only modulate
renal activity when RAS is overactivated. The effect of H2S on
renin activity has been illustrated in Figure 2B.
H2S as an O2 Sensor in the Kidney
Essentially all H2S generation is independent of O2; however,
the metabolism of H2S is a process highly relying on O2 (Olson,
2015). Accumulating evidence suggests that H2S is an O2 sensor
in kidney, especially in medulla (Figure 2C). The availability of
O2 in renal medulla is lower compared with that in renal cortex
resulting in a higher abundance of H2S in this region (Koning
et al., 2015). Provided mitochondria can use H2S as an electron
donor for ATP production (Fu et al., 2012; Teng et al., 2013),
it will be interesting to hypothesize that H2S might be a direct
source of energy in renal medulla. During hypoxia, O2 reduction
leads to further accumulation of H2S which help to recover O2
supply by increasing medullary blood flow and inhibition of
tubular transport (Beltowski, 2010). In addition, CBS and CSE
can translocate into mitochondria and stimulate H2S production
under hypoxic circumstances (Fu et al., 2012; Teng et al., 2013).
The mitochondria derived H2S may directly participate in ATP
production. Currently, emerging physiological evidence for H2S
mediated O2 sensing has also been suggested in various O2
sensing tissues including cardiovascular system (Olson et al.,
2006; Olson and Whitfield, 2010), respiratory system (Hu et al.,
2008), gastrointestinal tract (Dombkowski et al., 2011) et al.
However, the downstream effectors of H2S mediated O2 sensing
remains to be determined.
H2S IN ACUTE KIDNEY INJURY
Acute kidney injury (formerly known as acute renal failure)
is defined as a syndrome characterized by rapid loss of the
kidney’s excretory function. It is the clinical manifestation of
several disorders that affect the kidney acutely (Bellomo et al.,
2012). Here, H2S effects in three types of acute kidney injury
will be discussed namely renal IRI, obstructive nephropathy, and
cisplatin nephrotoxicity.
H2S in Renal Ischemia/Reperfusion
Injury
Renal IRI is a major cause of acute kidney injury. The
pathophysiological mechanism underlying renal IRI is very
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complex containing ATP depletion, calcium overload, ROS
generation, apoptotic and inflammatory responses et al (Eltzschig
and Eckle, 2011). The engagement of endogenous H2S in
renal IRI has been thoroughly demonstrated in various studies.
Specifically, both mRNA and protein levels of CSE and CBS
are apparently reduced upon IRI along with the reduction of
H2S level in kidney and plasma (Xu et al., 2009; Han et al.,
2015), although mechanisms underlying IRI caused CSE and
CBS reduction are still not revealed. In addition, inhibition of
either CSE or CBS by their pharmacological inhibitors severely
aggravates renal damage (Tripatara et al., 2008; Han et al., 2015)
indicating that the ischemic renal injury might, at least in part,
results from the impaired endogenous production of H2S. The
implication is supported by a recent finding that CSE-deficiency
associates with increased renal damage and mortality after renal
IRI which might be due to the enhanced production of ROS
(Bos et al., 2013). Subsequently, the effect of exogenous H2S was
extensively studied in various renal IRI scenarios (Tripatara et al.,
2008, 2009; Bos et al., 2009, 2013; Xu et al., 2009; Simon et al.,
2011; Hunter et al., 2012; Zhu et al., 2012; Azizi et al., 2015; Han
et al., 2015; Ahmad et al., 2016) which have been summarized in
Table 1. In most studies, an H2S donor, NaHS, was employed and
exerted protective effects likely through anti-inflammatory, anti-
apoptotic, and anti-oxidative responses. Comparing with new
generation synthetic H2S donors like GYY4137, NaHS is less
physiologically accurate H2S producer (Li et al., 2008; Yu et al.,
2010). Recently, GYY4137 was shown to attenuate heart damage
by inhibiting activation of NF-κB and MAPK signaling in a rat
model of myocardial IRI (Meng et al., 2015a,b). Thus, studies are
warranted to study whether slow H2S donors like GYY4137 can
protect kidney form IRI. Besides, it is worth noting that AP39,
a mitochondrially targeted donor of H2S, was recently found to
inhibit intracellular ROS formation caused by glucose oxidase
and protect kidney from IRI caused damage in rats (Ahmad et al.,
2016). The study implies the importance of mitochondria H2S in
the pathology of renal IRI which needs to be determined in the
future.
H2S in Obstructive Nephropathy
Obstructive nephropathy is a type of renal injury caused by
obstruction of the genitourinary tract. Renal fibrosis after ureteral
obstruction is implicated in the development of obstructive
nephropathy (Boor et al., 2010). Hu’s group showed that ureteral
obstruction impaired endogenous production of H2S by reducing
the expression level of CBS (Song et al., 2014). Renal fibrosis
is attenuated when exogenous H2S is administered suggesting
an inhibitory effect of H2S on renal fibrosis (Song et al., 2014).
In cultured kidney fibroblast, NaHS is able to inhibit cell
proliferation and block the differentiation into myofibroblasts by
suppressing transforming growth-β1-Smad and MAPK signaling
pathways (Song et al., 2014). Furthermore, administration of
NaHS also prevents the disruption of renal function caused by
ureteral obstruction (Jiang et al., 2014; Song et al., 2014; Dursun
et al., 2015). A recent study from Sener’s group (Lin et al.,
2016) showed that H2S slow releasing donor GYY4137 mitigated
cortical loss, inflammatory damage and tubulointerstitial fibrosis
in a rat model of obstructive nephropathy. Taken together, these
results suggest a potential use of H2S donor as a rescue in
obstructive nephropathy.
H2S in Cisplatin Nephrotoxicity
Cisplatin is a major therapeutic drug for solid tumors, but
causes severe nephrotoxicity. Over 30% of patients receiving
high dose cisplatin develop renal dysfunction (Pabla and Dong,
2008). However, effective treatment of cisplatin induced renal
failure is still lacking. Extensive research revealed that oxidative
stress and inflammatory response are the major driving forces
for cisplatin induced renal toxicity (Pabla and Dong, 2008;
Peres and da Cunha, 2013). Given the well-known inhibitory
effects of H2S on oxidative stress and inflammation (Łowicka
and Bełtowski, 2006), it is reasonable to hypothesize that H2S
is protective against cisplatin nephrotoxicity. However, the role
of H2S is rather controversial due to conflicting data in this
field. Coimbra and others (Della Coletta Francescato et al., 2011)
firstly showed that cisplatin upregulated the expression level
of CSE after 3 days upon cisplatin treatment in a rat model.
When PAG was administered with cisplatin, it was found that
PAG abolished the upregulation of CSE and rescued cisplatin
caused renal damage by suppressing inflammation and apoptosis
(Della Coletta Francescato et al., 2011). In contrast to this study,
administration of NaHS ameliorates the kidney dysfunction and
damage in cisplatin treated rat (Ahangarpour et al., 2014). Liu
et al. (2016) recently showed that both CSE and CBS levels
were severely decreased upon cisplatin treatment in mouse
after 3 days. However, pretreatment with H2S slow releasing
donor GYY4137 aggravates cisplatin induced renal damage by
increasing inflammatory response (Liu et al., 2016). However,
several defects on the use of GYY4137 need to be pointed out in
the study. As they used a rather low dose of GYY4137 (21 mg/kg),
it is possible that H2S might be not generated sufficiently (Li et al.,
2008; Yu et al., 2010; Meng et al., 2015a,b; Lin et al., 2016). In
addition, to rule out the possibility that the chemical backbone
of GYY4137 molecule has aggravated cisplatin nephrotoxicity,
ZYJ1122 (Lee et al., 2011), a structure analog of GYY4127, should
be included for the study. Despite the promising protective effect
of H2S, however, it is still far from the conclusion that H2S is
protective in cisplatin nephrotoxicity. In future, more studies are
still needed to further investigate (1) the change of CSE and CBS
expression level in a time course dependant manner; (2) the effect
of endogenous H2S by using genetic mouse rather than non-
specific CBS/CSE inhibitors; (3) the effect of exogenous H2S by
using different H2S (NaHS, GYY4137, AP39) donors in parallel.
H2S IN CHRONIC KIDNEY DISEASE
Chronic kidney disease is a general term for heterogeneous
disorders affecting kidney structure and function. In western
countries, it is generally associated with old age, diabetes,
hypertension, obesity, and cardiovascular disease (Levey
and Coresh, 2012). Diabetic nephropathy and hypertensive
nephropathy are considered as presumed pathological entities.
The role of H2S in these two types of CKD will be reviewed
below.
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TABLE 1 | Comparison of the renal protective effect of H2S against ischemic/reperfusion injury.
Treatment I/R protocol Species/tissue Effects of H2S Mechanism Reference
NaHS (100 µmol/kg,
i.p., 30 min prior to
ischemia)
I (30 min)/R (24 h) C57BL/6 mice Improved renal function – Tripatara et al., 2008
NaHS (1 mg/kg, i.p.,
15 min prior to
ischemia)
I (30 min)/R (24 h) C57BL/6 mice Improved renal
function; reduced renal
injury, and mortality
Anti-oxidation Bos et al., 2009
NaHS (100 µg/kg, i.p.,
15 min prior to
ischemia)
I (45 min)/R (6 h) Sprague-Dawley rat Improved renal
function; reduced renal
injury
Anti-oxidation;
anti-apoptosis
Tripatara et al., 2009
NaHS (500 µg/kg, i.p.,
first dose at 2 days
after ischemia; then
daily)
I (30 min)/R (8 days) C57BL/6 mice Accelerated kidney
recovery and tubular
cell regeneration
Anti-oxidation Xu et al., 2009
NaHS (100 µmol/kg,
topically onto the
kidneys 15 min before
ischemia and 5 min
before reperfusion)
I (45 min)/R (6 h) Wistar rat Improved renal
function; reduced renal
injury
Anti-apoptosis;
anti-MAPK; anti-NF-kB
Simon et al., 2011
H2S (100 ppm, 30 prior
to ischemia)
I (30 min)/R (24 h) C57BL/6 mice Improved renal
function; reduced renal
injury
Induction of
hypometabolism
Hunter et al., 2012
Na2S (initial bolus
0.2 mg/kg followed by
continuous i.v.
2 mg/kg/h during the
2 h before aortic
occlusion, 0.5 mg/kg/h
during the 90 min of
aortic occlusion, and
1 mg/kg/h during the
8-h reperfusion period)
I (2 h)/R (8 h) Local pig Improved renal
function; reduced renal
injury
Anti-apoptosis;
anti-oxidation;
anti-NF-kB
Zhu et al., 2012
NaHS (150 µmol/kg,
i.p., 30 min prior to
ischemia)
I (1 h)/R (2 h); warm
ischemia
Lewis rat Improved renal
function; reduced renal
injury
Anti-inflammation Bos et al., 2013
Na2S (i.v.; a bolus of
100 µg/kg was given
10 min before
reperfusion, followed by
an infusion of 1 mg/kg
given continuously for
30 min after
reperfusion)
I (1 h)/R (7 days) Large white pig Improved renal
function; reduced renal
injury
Anti-inflammation Azizi et al., 2015
NaHS (75 µmol/kg; i.p.;
10 min prior to
ischemia and
immediately before
reperfusion)
I (55 min)/R (24 h) Wistar rat Improved renal
function; reduced renal
injury
Anti-apoptosis;
anti-oxidation
Han et al., 2015
AP39 (0.3 mg/kg; i.p.;
5 min before
reperfusion)
I (30 min)/R (24 h) Sprague-Dawley rat Improved renal
function; reduced renal
injury
Anti-apoptosis;
anti-oxidation
Ahmad et al., 2016
i.p., intraperitoneal; i.v., intravenous; I/R, ischemia/reperfusion; MAPK, mitogen-activated protein kinase.
H2S in Diabetic Nephropathy
Diabetic nephropathy is the number one leading cause of CKD
in western countries. Morphologically, DN is characterized by
hypertrophy induced kidney growth and excessive accumulation
of extracellular matrix proteins, eventually proceeding to fibrosis
of glomerular and tubulointerstitial compartments (Cooper,
1998; Dronavalli et al., 2008). Current evidence suggests an active
role of H2S in the pathogenesis of DN. Plasma H2S level in
DN patients is significantly lower than that in non-DN patients
undergoing chronic hemodialysis (Li et al., 2014). High urinary
sulfate concentration, a reflection of high plasma H2S level, is
associated with reduced risk of renal disease progression in type
2 diabetes (van den Born et al., 2016) and slower decline in Cr51-
EDTA-assessed GFR in DN patients (Andresdottir et al., 2013).
Recent data suggested that the renal expression of H2S producing
enzyme CBS and CSE is down-regulated in pancreatic CaMTg
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diabetic mice (Yamamoto et al., 2013), C57BL/KsJ lepr−/− db/db
mice (Lee et al., 2012), STZ-diabetic rats (Yuan et al., 2011), and
Akita diabetic mice (Kundu et al., 2013). Inhibition of CSE with
PAG mimics high glucose-induced glomerular podocyte injury
(Liu et al., 2015), implying a contributive role of endogenous H2S
in DN. The mechanisms underlying CBS and CSE reduction have
been also studied. Kundu et al. (2013) showed that MMP-9 was
upregulated in Akita diabetic mice along with the reduction of
CBS and CSE. When MMP-9 is knocked out, the expression of
the two H2S producing enzyme namely CSE and CBS shows a
trend toward baseline despite hyperglycemia (Kundu et al., 2013)
suggesting that MMP-9 regulates CBS and CSE expression in DN
(Figure 3A).
Meanwhile, exogenous H2S has been proved to be effective
in in vitro and in vivo DN models. High glucose caused cell
proliferation and collagen formation are attenuated by NaHS in
cultured messangial cells (Yuan et al., 2011) and tubular cells
(Safar and Abdelsalam, 2015). Moreover, NaHS alone (Yuan et al.,
2011; Ahmad et al., 2012; Lee et al., 2012; Kundu et al., 2013;
Xue et al., 2013; Zhou et al., 2014; Liu et al., 2015; Safar and
Abdelsalam, 2015; Qian et al., 2016) or with losartan (Kaur et al.,
2015) ameliorates renal dysfunction and fibrosis formation in
various DN related animal models. At least three mechanisms
(Figure 3B) are implicated in H2S mediated protective effect in
DN: (1) Inhibition of ROS formation by activating Nrf2 pathway.
Hyperglycemia induces intracellular ROS which upregulates the
expression of MMP-9 (Kundu et al., 2013). MMP-9 plays a
major role in diabetic renovascular remodeling. In a STZ induced
diabetic rat model, H2S was found to reduce high glucose
induced oxidative stress by activating the Nrf2 antioxidant
pathway and thereby the level of MMP-9 (Zhou et al., 2014); (2)
AMPK activation. Matrix protein deposition requires stimulation
of protein synthesis. In DN, PI3K/Akt/mTORC1 signaling is
activated due to the suppression of AMPK activity (Yuzawa,
2012). The inactivation of AMPK was found to be partially
ascribed to the reduction of H2S level (Lee et al., 2012). NaHS
dose- and time- dependently activates the phosphorylation of
AMPK and inhibits the stimulation of mTOR (Lee et al., 2012).
As a result, mTOR mediated protein synthesis is inhibited which
partially accounts for the protective effect of H2S in DN. (3)
Stimulation of NO formation. Hyperglycemia upregulates NOX4
expression resulting in the generation of intracellular ROS and
laminin γ1, both of which contribute to renovascular remodeling
(Gorin et al., 2015). Expression of NOX4 can be attenuated by
FIGURE 3 | Hydrogen sulfide in DN. (A) ROS mediated MMP-9 up-regulation reduces the level of CBS and CSE in DN. (B) Mechanisms underlying the protective
effect of H2S in DN. (1) H2S inhibits ROS formation by activating Nrf2 pathway; (2) H2S activates AMPK, thereby suppressing PI3K/Akt/mTORC1 signaling and
subsequent protein synthesis; (3) H2S stimulates NO formation by induction of iNOS expression which inhibits NOX4 level and ROS production. ROS, reactive
oxygen species; MMP-9, matrix metalloproteinase-9; AMPK, AMP-activated protein kinase; NO, nitric oxide; iNOS, inducible nitric oxide synthase; mTOR,
mechanistic target of rapamycin.
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H2S (Kamat et al., 2015). L-NAME, a NOS inhibitor, abolished
the effect of H2S (Feliers et al., 2016). Further study showed that
H2S upregulates the protein expression of iNOS but not that of
eNOS (Feliers et al., 2016). Moreover, iNOS siRNA can block the
effect of H2S (Feliers et al., 2016) suggesting a role for NO in
H2S mediated protective effect in DN. Interestingly, NO can also
stimulate the activity of CSE and H2S production (Nagpure and
Bian, 2016) suggesting a cross-talk interaction between these two
pathways.
H2S in Hypertensive Nephropathy
Hypertensive nephropathy, a result of chronic hypertension,
is the second leading cause of CKD worldwide (Hart and
Bakris, 2010). Long time of high BP load results in damages
of kidney, especially in glomerulus. When kidney cannot
function properly, it fails to regulate BP. In turn, BP will
rise up which further aggravates renal damage (Bidani and
Griffin, 2004). Extensive evidence suggests a role of H2S in
BP control. Genetic deletion of CSE causes hypertension and
diminished endothelium dependent vasorelaxation (Yang et al.,
2008). Similar with this, inhibition of both CBS and CSE also
increases BP in rat (Roy et al., 2012). These data implies that
H2S is a physiologic regulator of BP. Further studies suggest that
H2S functions as both an EDHF (Mustafa et al., 2011; Edwards
et al., 2012; Tang et al., 2013) and an EDRF (Wang, 2009).
The BP lowering effect of exogenous H2S has been subsequently
determined. Our group first showed that H2S donor, NaHS,
attenuated BP by inhibiting plasma renin activity in a 2K1C
rat model (Lu et al., 2010). Thereafter, NaHS was demonstrated
to reduce BP in spontaneous hypertensive rats (Ahmad et al.,
2014), angiotensin II treated mice (Al-Magableh et al., 2015),
and sFlt transgenic mice (Holwerda et al., 2014). Additionally,
renal protective effects of H2S have also been reported in
hypertensive nephropathy. sFlt overexpression in mouse results
in hypertension with proteinuria and glomerular endothelosis, all
of which are apparently attenuated by administration of NaHS
(Holwerda et al., 2014). Further study suggests an involvement
of VEGF in this H2S mediated effect (Holwerda et al., 2014).
Both H2S and tempol were found to alleviate renal dysfunction
in a spontaneous hypertensive rat model by suppressing ROS
formation (Ahmad et al., 2014). Recently, Jin’s group reported
that either NaHS or its metabolite sodium thiosulfate attenuated
angiotensin II induced proteinuria, renal dysfunction, and
structural deterioration in rat (Al-Magableh et al., 2015). Further
studies suggested that the renal effects of H2S were partially
mediated by suppression of epithelial sodium channel (Zhang
et al., 2013; Wang et al., 2015). Taken together, H2S might be an
ideal candidate for the treatment of hypertensive nephropathy.
FUTURE DIRECTIONS
Role of Mitochondrial H2S Pathway in
Kidney Diseases
In contrast to the extensive studies on CBS and CSE in
various kidney diseases, the role of 3-MST is largely neglected
although definitive evidence has demonstrated its abundance
in kidney (Aminzadeh and Vaziri, 2012; Shibuya et al., 2013;
Kimura, 2014). 3-MST resides in mitochondria and is the major
producer of mitochondria derived H2S. 3-MST silencing was
reported to reduce bioenergetic parameters and H2S can serve
as an electron donor in mammalian cells (Modis et al., 2013),
indicating a possible physiological role of 3-MST/H2S pathway
in maintaining mitochondrial electron transport and cellular
bioenergitics. Renal ischemia is the most common cause of acute
kidney injury. Hypoxia leads to the inhibition of mitochondrial
respiratory chain by deprivation of O2. What will happen if H2S
is supplemented into the mitochondria when hypoxia occurs?
Szabo’s group (Ahmad et al., 2016) showed that mitochondrially
targeted H2S donor AP39 ameliorated renal damage in an
ischemia/reperfusion rat model, suggesting possible involvement
of 3-MST/H2S pathway in the pathogenesis although the change
of 3-MST level and activity upon hypoxia was not determined.
Additionally, the importance of 3-MST/H2S pathway is also
suggested by the fact that ROS, the common cause of renal
diseases of all types, induces the translocation of CBS and CSE
into mitochondria (Fu et al., 2012). Thus, the revelation of the
involvement of 3-MST in kidney diseases is of great value.
Targeting DAO/3-MST Pathway for H2S
Delivery to Kidney
Safety is always a concern when administrating H2S systemically
due to its well-known toxicity (Guidotti, 2010; Hirose, 2010)
which might hamper its development as therapeutics. This safety
issue might be diminished by specific delivery of H2S to the
targeted organs. Unfortunately, such organ specific H2S donor
is not reported. The discovery of DAO/3-MST pathway might
provide a clue about how to deliver H2S specifically into the
kidney. The pathway uniquely utilizes D-cysteine rather than
L-cystein to produce H2S and exclusively exists in cerebellum
and kidney (Shibuya et al., 2013). When D-cysteine is given, it
attenuates IRI in kidney with higher potency than L-cysteine
(Shibuya et al., 2013). As H2S is broadly renal protective as
we have reviewed above, D-cysteine might also ameliorate other
renal diseases. Direct administration of D-cysteine induces the
generation of H2S in both cerebellum and kidney (Shibuya et al.,
2013). Nevertheless, it is possible that structural modification of
D-cysteine can generate a novel moiety providing D-cysteine to
kidney but not cerebellum due to the impermeability of blood–
brain barrier. This hypothesis warrants further investigation.
Test of Drug-Like H2S Donors in Kidney
Disease
To date, most studies of H2S effect in kidney have been largely
restricted to the use of NaHS as an H2S donor despite of rare
exceptions with GYY4137 or AP39. However, NaHS releases H2S
at an uncontrolled manner (Li et al., 2008) and is unlikely to
be a therapeutic agent (Szabo, 2007). Numerous drug-like H2S
donors have been developed and some of them are under the
investigation in clinical trials. For instance, an orally active H2S
donor SG-1002 is proven to be safe in humans and underwent
Phase II study for heart failure (ClinicalTrials.gov identifier:
NCT01989208); Antibe Therapeutics are conducting several
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preclinical or clinical studies with their various H2S donors
(ATB-346 for osteoarthritis; ATB-352 for Acute pain; ATB-350
for Thrombosis). The information on these H2S releasing donors
can be found in Wallace and Wang (2015). Testing of these drug-
like H2S donors will not only consolidate the protective effect of
H2S, but also shed light on the translation of H2S as a therapeutic
agent for renal diseases.
Understanding the Molecular
Mechanism of H2S
Last, but not least, one should bear in mind that the molecular
mechanisms underlying H2S effect is still not well-understood. It
seems that H2S may partially exert its effect as a reducing agent
to eliminate ROS (Bruce King, 2013), while its effects on gene
expression may be related to specific molecular targets like NF-κB
and the ERK pathways (Oh et al., 2006). However, the molecular
details are still unclear. Thus, the in-depth portrayal about the
interaction between H2S and its target protein will be interesting.
CONCLUSION
After recognition as the third gaseous mediator after NO and CO,
the biological actions of H2S are still expanding. In kidney, it
is actively participating in the renal regulation in physiological
condition. Due to the regulatory role of kidney in the body,
it is possible that H2S has far-reaching actions by modulating
renal function which needs to be uncovered. Because of the
significant role of H2S in renal physiology, it is not surprising
that dysfunction of H2S contributes to the pathogenesis of kidney
related diseases. Thereafter, administration of H2S mainly with
NaHS was proven to rescue kidney damages in animal models
with various types of kidney diseases. In the future, drug like H2S
donors need to be tested to translate H2S as a treatment for renal
diseases in clinical. Besides, in-depth studies of H2S mediated
molecular actions are also needed to complete our understanding
of the role of H2S in both renal physiology and pathology.
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